Connect with us

Health

UK approves Moderna’s COVID-19 vaccine for children aged six to 11

Britain’s medicines regulator said on Thursday it had approved the use of Moderna Inc’s COVID-19 vaccine in children between six and 11 years, as the country bolsters itself for fighting coronavirus infections.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required standards of safety, quality and effectiveness.

For the latest headlines, follow our Google News channel online or via the app.

Spikevax was already approved in Britain for those over 12 years, and the extension to include younger children comes hours after the regulator approved French firm Valneva's easy-to-store COVID-19 vaccine for adults up to 50 years of age.
MHRA chief June Raine said in a statement it would be up to Britain’s Joint Committee on Vaccination and Immunization to advise on whether Moderna’s vaccine will be offered to the younger group as part of the country’s immunization program.

Read more:

New COVID-19 vaccine may also protect cancer patients with weak immunity: Study

Pfizer to expand COVID-19 booster shots to healthy five to 11-year-olds in US

Worldwide COVID-19 cases surpass 500 million as omicron variant BA.2 surges

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.

Health

BioNTech, Pfizer to start testing universal vaccine for COVID-19

Germany’s BioNTech, Pfizer’s partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.

Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.

For more coronavirus news, visit our dedicated page.

In presentation slides posted on BioNTech’s website for its investor day, the German biotech firm said its aim was to “provide durable variant protection.”

The two partners, makers of the Western world’s most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sub lineages.

The virus’ persistent mutation into new variants that more easily evade vaccine protection, as well as waning human immune memory, have added urgency to the search by companies, governments and health bodies for more reliable tools of protection.

For the latest headlines, follow our Google News channel online or via the app.

As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.

BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, which it acquired in October last year.

The Vienna-based antibiotics developer has done work on enzymes, made by bacteria-killing viruses, that break through the bacterial cell wall.

Drug-resistant infections are on the rise, driven by antibiotic overuse and leaks into the environment in antibiotics production.

Public health researchers put the combined number of people dying per year from antibiotic-resistant infections in the United States and the European Union at close to 70,000.

Read more:

China’s Xi warns against ‘herd immunity,’ says COVID-Zero policy works best

US FDA advisers meet to discuss design of future COVID-19 vaccines

US CDC advisers weigh Moderna COVID-19 vaccine for teens, older children

Continue Reading

Health

China’s Xi warns against ‘herd immunity,’ says COVID-Zero policy works best

President Xi Jinping declared COVID-Zero the most “economic and effective policy for China,” during a symbolic visit to Wuhan in which he cast the strategy as proof of the superiority of the country’s political system.

Xi said during a trip Tuesday to the central Chinese city where the virus first emerged in late 2019 that relaxing COVID-19 controls would risk too many lives in the world’s most populous country. China would rather endure some temporary impact on economic development than let the virus hurt people’s safety and health, he said, in remarks reported Wednesday by state media.

For more coronavirus news, visit our dedicated page.

“Our country has a large population, such strategies as ‘herd immunity’ and ‘lying flat’ would lead to consequences that are unimaginable,” Xi said, according to the official Xinhua News Agency.

The benchmark CSI 300 equities gauge extended losses, ending Wednesday’s session down 1.5 percent, its biggest decline in more than a month. The offshore yuan, which initially declined as much as 0.2 percent on Xi’s comments, pared losses to 6.7032 per dollar as of 4:45 p.m. local time.

The comments represent the clearest sign yet that Xi was willing to expend the political power he’s amassed over the past decade defending a policy that has required locking down large swaths of the country’s most economically important cities for weeks on end. The president characterized Covid Zero as connected to the Communist Party’s “nature and purposes.”

“We have the leadership of CCP, we have the communities as the foundation at grassroots level, we have the capability and strength to implement dynamic-clearance policy until reaching the final victory,” Xi said, using China’s preferred term for the approach.

Growth Target

The comments come in the run up to a pivotal party congress later this year, in which Xi is expected to secure a precedent-breaking third term in power. By increasingly tying COVID-Zero to his own prestige as a leader, Xi is making it riskier for critics of the policy to speak up and also raising the political stakes for himself.

China’s Covid outbreaks and an ongoing property market slump have put the government’s economic growth target of around 5.5 percent out of reach. Economists surveyed by Bloomberg predict growth of just 4.1 percent for this year.

“Xi Jinping’s comments in Wuhan suggest that China’s top leadership sees COVID as a legitimate reason to miss the economic growth objectives and that China’s overall COVID stance is unlikely to change any time soon,” said Louis Kuijs, Asia Pacific chief economist at S&P Global Ratings. “In turn, that means that new outbreaks will continue to pose serious risks to the economy and that economic sentiment will continue to be affected.”

In Wuhan, Xi said China “needs to promote the stable and healthy development of the economy as much as possible at the same time as carrying out the work of pandemic prevention.” Xi also said the country needed to be more self-reliant on developing cutting edge technologies, especially in chip industry and high-end manufacturing, saying the country must “firmly hold the lifeline of science and technology in its own hands.”

Testing Protocol

Xi’s remarks come after the country managed to quell its most serious outbreaks since the Wuhan crisis: both Shanghai and Beijing reported zero local cases on Monday, for the first time since February 19, with the financial hub in particular emerging from a bruising two-month lockdown.

The omicron outbreak has tested its playbook, but China appears to have emerged from that with a new protocol for maintaining COVID-Zero indefinitely. While an easing of travel quarantine buoyed markets on Tuesday as a sign of reopening, officials in the same document codified a standardized approach to mass testing and lockdown that local officials should follow.

China’s 1.4 billion people live in a new normal of constant testing and tracking. In the capital of Beijing, residents are required to show a green code on a mobile app that tracks their health status, and take a COVID-19 test every three days to enter any public venue, including restaurants, shops, and mass transportation. Even kids over age three must be tested to play in the park.

Xi’s comments were likely to dash hopes that China was cautiously embarking on an exit plan.

“We would rather temporarily affect a little economic development, than to risk harming people’s life safety and physical health, especially the elderly and children,” he said Tuesday.

Read more:

Hong Kong steps up COVID-19 testing as details of President Xi’s visit emerge

Nose swabs still best method to test for COVID-19: Study

Beijing to reopen schools, Shanghai declares victory over COVID-19

Continue Reading

Health

US FDA advisers meet to discuss design of future COVID-19 vaccines

Outside advisers to the US Food and Drug Administration are meeting on Tuesday to discuss whether to change the design of COVID-19 vaccines in order to combat future variants of the coronavirus.
The updated shots are likely to be redesigned to fight the Omicron variant of the coronavirus, experts say. The exact composition of the retooled shots and whether they also will include some of the original vaccine alongside new components will be considered at the meeting.

For the latest headlines, follow our Google News channel online or via the app.

Pfizer Inc, Moderna Inc and Novavax Inc are scheduled to present data at the meeting. All three companies have been testing versions of their vaccines updated to combat the BA.1 Omicron variant that was circulating and led to a massive surge in infections last winter.
Both Moderna and Pfizer with partner BioNTech have said that their respective redesigned vaccines generate a better immune response against BA.1 than their current shots that were designed for the original virus that emerged from China.

For more coronavirus news, visit our dedicated page.

They have said that their new vaccines also appear to work against the more recently circulating BA.4 and BA.5 Omicron subvariants, even though that protection is not as strong as against BA.1.
Experts also want to know if the new shots will increase protection against severe disease and death for younger, healthier people or merely offer a few months additional safeguard against mild infection.
Scientists who have questioned the value of booster shots for young and healthy people have said a broad campaign is not needed with an updated shot either.
Others experts have championed any additional protection new vaccines may offer.

Read more:

Hong Kong steps up COVID-19 testing as details of President Xi’s visit emerge

Pfizer says omicron-fighting COVID-19 shots prompt strong immune response

Nose swabs still best method to test for COVID-19: Study

Continue Reading

Trending